West Pharma (WST) Tops Q3 EPS by 35c, provides guidance

West Pharma (NYSE: WST) reported Q3 EPS of $1.85, $0.35 better than the analyst estimate of $1.50. Revenue for the quarter came in at $746.9 million versus the consensus estimate of $709.3 million.

GUIDANCE:

West Pharma sees FY2024 EPS of $6.55-$6.75, versus the consensus of $6.41. West Pharma sees FY2024 revenue of $2.875-2.905 billion, versus the consensus of $2.874 billion.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Morgan Stanley continues to recommend exposure to the broadening theme
• McGraw Hill adds grades 4-5 and Calculus II to its ALEKS portfolio
• UBS Reiterates Buy Rating on Williams Companies (WMB)